Intensity Therapeutics Q3 net loss narrows to $2.7 mln

Reuters11-07

Intensity <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 net loss narrows to $2.7 mln

Overview

Intensity Therapeutics Q3 net loss narrows to $2.7 mln from $3.5 mln last year
Company raised $13.6 mln since Q3 start, extending cash runway to Q1 2027
Research and development expenses decreased due to lower clinical trial costs

Outlook

Company plans to reinitiate INVINCIBLE-4 Study enrollment in Q1 2026
Company aims to restart INVINCIBLE-3 Study enrollment once funding is secured
Cash runway extended until end of Q1 2027

Result Drivers

CLINICAL TRIAL EXPENSES - Trial expenses fell $0.4 mln due to lower INVINCIBLE-3 study costs, helping lower overall R&D costs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Basic EPS		-$0.06
Q3 Operating Income		-$2.73 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Intensity Therapeutics Inc is $3.00, about 81% above its November 5 closing price of $0.57

Press Release: ID:nPn5n20YQa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581434420?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581434420","market":"us","top_or_hot":-1,"title":"Intensity Therapeutics Q3 net loss narrows to $2.7 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Intensity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss narrows to $2.7 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Intensity Therapeutics Q3 net loss narrows to $2.7 mln from $3.5 mln last year</p></li><li><p>Company raised $13.6 mln since Q3 start, extending cash runway to Q1 2027</p></li><li><p>Research and development expenses decreased due to lower clinical trial costs</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to reinitiate INVINCIBLE-4 Study enrollment in Q1 2026</p></li><li><p>Company aims to restart INVINCIBLE-3 Study enrollment once funding is secured</p></li><li><p>Cash runway extended until end of Q1 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL TRIAL EXPENSES - Trial expenses fell $0.4 mln due to lower INVINCIBLE-3 study costs, helping lower overall R&amp;D costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.06</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$2.73 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Intensity Therapeutics Inc is $3.00, about 81% above its November 5 closing price of $0.57</p></li></ul><p>Press Release: <span>ID:nPn5n20YQa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intensity Therapeutics Q3 net loss narrows to $2.7 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntensity Therapeutics Q3 net loss narrows to $2.7 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Intensity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss narrows to $2.7 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Intensity Therapeutics Q3 net loss narrows to $2.7 mln from $3.5 mln last year</p></li><li><p>Company raised $13.6 mln since Q3 start, extending cash runway to Q1 2027</p></li><li><p>Research and development expenses decreased due to lower clinical trial costs</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to reinitiate INVINCIBLE-4 Study enrollment in Q1 2026</p></li><li><p>Company aims to restart INVINCIBLE-3 Study enrollment once funding is secured</p></li><li><p>Cash runway extended until end of Q1 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL TRIAL EXPENSES - Trial expenses fell $0.4 mln due to lower INVINCIBLE-3 study costs, helping lower overall R&amp;D costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.06</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$2.73 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Intensity Therapeutics Inc is $3.00, about 81% above its November 5 closing price of $0.57</p></li></ul><p>Press Release: <span>ID:nPn5n20YQa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INTS","symbol_name":"Intensity Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1IM:1","article_id":"2581434420","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581434420","pubTimestamp":1762465011,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Intensity Therapeutics Q3 net loss narrows to $2.7 mlnOverviewIntensity Therapeutics Q3 net loss narrows to $2.7 mln from $3.5 mln last yearCompany raised $13.6 mln since Q3 start, extending cash runw","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INTS":"Intensity Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Intensity Therapeutics第三季度净亏损收窄至270万美元","themeId":"7026f4aef5369e29e112f6f82189519d","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INTS":0.9},"content_text":"Intensity Therapeutics Q3 net loss narrows to $2.7 mlnOverviewIntensity Therapeutics Q3 net loss narrows to $2.7 mln from $3.5 mln last yearCompany raised $13.6 mln since Q3 start, extending cash runway to Q1 2027Research and development expenses decreased due to lower clinical trial costsOutlookCompany plans to reinitiate INVINCIBLE-4 Study enrollment in Q1 2026Company aims to restart INVINCIBLE-3 Study enrollment once funding is securedCash runway extended until end of Q1 2027Result DriversCLINICAL TRIAL EXPENSES - Trial expenses fell $0.4 mln due to lower INVINCIBLE-3 study costs, helping lower overall R&D costsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Basic EPS-$0.06Q3 Operating Income-$2.73 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"Wall Street's median 12-month price target for Intensity Therapeutics Inc is $3.00, about 81% above its November 5 closing price of $0.57Press Release: ID:nPn5n20YQaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581434420","isCrawlerRequest":true}